Report cover image

Global Respiratory Virus Infection Drugs Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 107 Pages
SKU # APRC20354729

Description

Summary

According to APO Research, The global Respiratory Virus Infection Drugs market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Respiratory Virus Infection Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Respiratory Virus Infection Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Respiratory Virus Infection Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of Respiratory Virus Infection Drugs include Teva Pharmaceutical Industries Ltd., Sanofi, Merck and Co., Inc., GlaxoSmithKline plc, AstraZeneca, Orion Corporation, F. Hoffmann-La Roche Ltd., Cipla, Inc. and CHIESI Farmaceutici S.p.A., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Respiratory Virus Infection Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Respiratory Virus Infection Drugs.

The Respiratory Virus Infection Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Respiratory Virus Infection Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Respiratory Virus Infection Drugs Segment by Company

Teva Pharmaceutical Industries Ltd.
Sanofi
Merck and Co., Inc.
GlaxoSmithKline plc
AstraZeneca
Orion Corporation
F. Hoffmann-La Roche Ltd.
Cipla, Inc.
CHIESI Farmaceutici S.p.A.
Boehringer Ingelheim International GmbH

Respiratory Virus Infection Drugs Segment by Type

Nasal Decongestants
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Antibiotics
Cough Suppressants
Others

Respiratory Virus Infection Drugs Segment by Application

Retail Pharmacies
Drug Stores
Hospital Pharmacies
Clinics
Others

Respiratory Virus Infection Drugs Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Virus Infection Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Respiratory Virus Infection Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Virus Infection Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Respiratory Virus Infection Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Respiratory Virus Infection Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Table of Contents

107 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Respiratory Virus Infection Drugs Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global Respiratory Virus Infection Drugs Sales Estimates and Forecasts (2020-2031)
1.3 Respiratory Virus Infection Drugs Market by Type
1.3.1 Nasal Decongestants
1.3.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
1.3.3 Antibiotics
1.3.4 Cough Suppressants
1.3.5 Others
1.4 Global Respiratory Virus Infection Drugs Market Size by Type
1.4.1 Global Respiratory Virus Infection Drugs Market Size Overview by Type (2020-2031)
1.4.2 Global Respiratory Virus Infection Drugs Historic Market Size Review by Type (2020-2025)
1.4.3 Global Respiratory Virus Infection Drugs Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America Respiratory Virus Infection Drugs Sales Breakdown by Type (2020-2025)
1.5.2 Europe Respiratory Virus Infection Drugs Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific Respiratory Virus Infection Drugs Sales Breakdown by Type (2020-2025)
1.5.4 South America Respiratory Virus Infection Drugs Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa Respiratory Virus Infection Drugs Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics
2.1 Respiratory Virus Infection Drugs Industry Trends
2.2 Respiratory Virus Infection Drugs Industry Drivers
2.3 Respiratory Virus Infection Drugs Industry Opportunities and Challenges
2.4 Respiratory Virus Infection Drugs Industry Restraints
3 Market Competitive Landscape by Company
3.1 Global Top Players by Respiratory Virus Infection Drugs Revenue (2020-2025)
3.2 Global Top Players by Respiratory Virus Infection Drugs Sales (2020-2025)
3.3 Global Top Players by Respiratory Virus Infection Drugs Price (2020-2025)
3.4 Global Respiratory Virus Infection Drugs Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global Respiratory Virus Infection Drugs Major Company Production Sites & Headquarters
3.6 Global Respiratory Virus Infection Drugs Company, Product Type & Application
3.7 Global Respiratory Virus Infection Drugs Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Respiratory Virus Infection Drugs Market CR5 and HHI
3.8.2 Global Top 5 and 10 Respiratory Virus Infection Drugs Players Market Share by Revenue in 2024
3.8.3 2023 Respiratory Virus Infection Drugs Tier 1, Tier 2, and Tier 3
4 Respiratory Virus Infection Drugs Regional Status and Outlook
4.1 Global Respiratory Virus Infection Drugs Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global Respiratory Virus Infection Drugs Historic Market Size by Region
4.2.1 Global Respiratory Virus Infection Drugs Sales in Volume by Region (2020-2025)
4.2.2 Global Respiratory Virus Infection Drugs Sales in Value by Region (2020-2025)
4.2.3 Global Respiratory Virus Infection Drugs Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global Respiratory Virus Infection Drugs Forecasted Market Size by Region
4.3.1 Global Respiratory Virus Infection Drugs Sales in Volume by Region (2026-2031)
4.3.2 Global Respiratory Virus Infection Drugs Sales in Value by Region (2026-2031)
4.3.3 Global Respiratory Virus Infection Drugs Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 Respiratory Virus Infection Drugs by Application
5.1 Respiratory Virus Infection Drugs Market by Application
5.1.1 Retail Pharmacies
5.1.2 Drug Stores
5.1.3 Hospital Pharmacies
5.1.4 Clinics
5.1.5 Others
5.2 Global Respiratory Virus Infection Drugs Market Size by Application
5.2.1 Global Respiratory Virus Infection Drugs Market Size Overview by Application (2020-2031)
5.2.2 Global Respiratory Virus Infection Drugs Historic Market Size Review by Application (2020-2025)
5.2.3 Global Respiratory Virus Infection Drugs Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America Respiratory Virus Infection Drugs Sales Breakdown by Application (2020-2025)
5.3.2 Europe Respiratory Virus Infection Drugs Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific Respiratory Virus Infection Drugs Sales Breakdown by Application (2020-2025)
5.3.4 South America Respiratory Virus Infection Drugs Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa Respiratory Virus Infection Drugs Sales Breakdown by Application (2020-2025)
6 Company Profiles
6.1 Teva Pharmaceutical Industries Ltd.
6.1.1 Teva Pharmaceutical Industries Ltd. Comapny Information
6.1.2 Teva Pharmaceutical Industries Ltd. Business Overview
6.1.3 Teva Pharmaceutical Industries Ltd. Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Teva Pharmaceutical Industries Ltd. Respiratory Virus Infection Drugs Product Portfolio
6.1.5 Teva Pharmaceutical Industries Ltd. Recent Developments
6.2 Sanofi
6.2.1 Sanofi Comapny Information
6.2.2 Sanofi Business Overview
6.2.3 Sanofi Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Sanofi Respiratory Virus Infection Drugs Product Portfolio
6.2.5 Sanofi Recent Developments
6.3 Merck and Co., Inc.
6.3.1 Merck and Co., Inc. Comapny Information
6.3.2 Merck and Co., Inc. Business Overview
6.3.3 Merck and Co., Inc. Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Merck and Co., Inc. Respiratory Virus Infection Drugs Product Portfolio
6.3.5 Merck and Co., Inc. Recent Developments
6.4 GlaxoSmithKline plc
6.4.1 GlaxoSmithKline plc Comapny Information
6.4.2 GlaxoSmithKline plc Business Overview
6.4.3 GlaxoSmithKline plc Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 GlaxoSmithKline plc Respiratory Virus Infection Drugs Product Portfolio
6.4.5 GlaxoSmithKline plc Recent Developments
6.5 AstraZeneca
6.5.1 AstraZeneca Comapny Information
6.5.2 AstraZeneca Business Overview
6.5.3 AstraZeneca Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 AstraZeneca Respiratory Virus Infection Drugs Product Portfolio
6.5.5 AstraZeneca Recent Developments
6.6 Orion Corporation
6.6.1 Orion Corporation Comapny Information
6.6.2 Orion Corporation Business Overview
6.6.3 Orion Corporation Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Orion Corporation Respiratory Virus Infection Drugs Product Portfolio
6.6.5 Orion Corporation Recent Developments
6.7 F. Hoffmann-La Roche Ltd.
6.7.1 F. Hoffmann-La Roche Ltd. Comapny Information
6.7.2 F. Hoffmann-La Roche Ltd. Business Overview
6.7.3 F. Hoffmann-La Roche Ltd. Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 F. Hoffmann-La Roche Ltd. Respiratory Virus Infection Drugs Product Portfolio
6.7.5 F. Hoffmann-La Roche Ltd. Recent Developments
6.8 Cipla, Inc.
6.8.1 Cipla, Inc. Comapny Information
6.8.2 Cipla, Inc. Business Overview
6.8.3 Cipla, Inc. Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Cipla, Inc. Respiratory Virus Infection Drugs Product Portfolio
6.8.5 Cipla, Inc. Recent Developments
6.9 CHIESI Farmaceutici S.p.A.
6.9.1 CHIESI Farmaceutici S.p.A. Comapny Information
6.9.2 CHIESI Farmaceutici S.p.A. Business Overview
6.9.3 CHIESI Farmaceutici S.p.A. Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 CHIESI Farmaceutici S.p.A. Respiratory Virus Infection Drugs Product Portfolio
6.9.5 CHIESI Farmaceutici S.p.A. Recent Developments
6.10 Boehringer Ingelheim International GmbH
6.10.1 Boehringer Ingelheim International GmbH Comapny Information
6.10.2 Boehringer Ingelheim International GmbH Business Overview
6.10.3 Boehringer Ingelheim International GmbH Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Boehringer Ingelheim International GmbH Respiratory Virus Infection Drugs Product Portfolio
6.10.5 Boehringer Ingelheim International GmbH Recent Developments
7 North America by Country
7.1 North America Respiratory Virus Infection Drugs Sales by Country
7.1.1 North America Respiratory Virus Infection Drugs Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America Respiratory Virus Infection Drugs Sales by Country (2020-2025)
7.1.3 North America Respiratory Virus Infection Drugs Sales Forecast by Country (2026-2031)
7.2 North America Respiratory Virus Infection Drugs Market Size by Country
7.2.1 North America Respiratory Virus Infection Drugs Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America Respiratory Virus Infection Drugs Market Size by Country (2020-2025)
7.2.3 North America Respiratory Virus Infection Drugs Market Size Forecast by Country (2026-2031)
8 Europe by Country
8.1 Europe Respiratory Virus Infection Drugs Sales by Country
8.1.1 Europe Respiratory Virus Infection Drugs Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe Respiratory Virus Infection Drugs Sales by Country (2020-2025)
8.1.3 Europe Respiratory Virus Infection Drugs Sales Forecast by Country (2026-2031)
8.2 Europe Respiratory Virus Infection Drugs Market Size by Country
8.2.1 Europe Respiratory Virus Infection Drugs Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe Respiratory Virus Infection Drugs Market Size by Country (2020-2025)
8.2.3 Europe Respiratory Virus Infection Drugs Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country
9.1 Asia-Pacific Respiratory Virus Infection Drugs Sales by Country
9.1.1 Asia-Pacific Respiratory Virus Infection Drugs Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific Respiratory Virus Infection Drugs Sales by Country (2020-2025)
9.1.3 Asia-Pacific Respiratory Virus Infection Drugs Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific Respiratory Virus Infection Drugs Market Size by Country
9.2.1 Asia-Pacific Respiratory Virus Infection Drugs Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific Respiratory Virus Infection Drugs Market Size by Country (2020-2025)
9.2.3 Asia-Pacific Respiratory Virus Infection Drugs Market Size Forecast by Country (2026-2031)
10 South America by Country
10.1 South America Respiratory Virus Infection Drugs Sales by Country
10.1.1 South America Respiratory Virus Infection Drugs Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America Respiratory Virus Infection Drugs Sales by Country (2020-2025)
10.1.3 South America Respiratory Virus Infection Drugs Sales Forecast by Country (2026-2031)
10.2 South America Respiratory Virus Infection Drugs Market Size by Country
10.2.1 South America Respiratory Virus Infection Drugs Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America Respiratory Virus Infection Drugs Market Size by Country (2020-2025)
10.2.3 South America Respiratory Virus Infection Drugs Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country
11.1 Middle East and Africa Respiratory Virus Infection Drugs Sales by Country
11.1.1 Middle East and Africa Respiratory Virus Infection Drugs Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa Respiratory Virus Infection Drugs Sales by Country (2020-2025)
11.1.3 Middle East and Africa Respiratory Virus Infection Drugs Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa Respiratory Virus Infection Drugs Market Size by Country
11.2.1 Middle East and Africa Respiratory Virus Infection Drugs Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa Respiratory Virus Infection Drugs Market Size by Country (2020-2025)
11.2.3 Middle East and Africa Respiratory Virus Infection Drugs Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis
12.1 Respiratory Virus Infection Drugs Value Chain Analysis
12.1.1 Respiratory Virus Infection Drugs Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Respiratory Virus Infection Drugs Production Mode & Process
12.2 Respiratory Virus Infection Drugs Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Respiratory Virus Infection Drugs Distributors
12.2.3 Respiratory Virus Infection Drugs Customers
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.